Swedish Match says EU bribes totalled 60 million euros

Tobacco producer Swedish Match claimed Friday it was offered the opportunity to pay 60 million euros ($78 million) to thwart new EU tobacco legislation in a scandal that has cost Europe's top health official his job.

"I can say that those are the amounts we are talking about, and I'd also like to stress that for us the amount of money does not matter," company spokesman Patrik Hildingsson told AFP.

Health and consumer commissioner John Dalli said he had been asked to resign on Tuesday after he was cited in a tobacco-linked influence peddling .

The European Commission announced his resignation on Tuesday "with immediate effect" following an investigation by OLAF, the EU's anti-fraud office, into a complaint by Swedish Match.

The Maltese commissioner has maintained his innocence, claiming he is the victim of a tobacco lobbying campaign to block tough new rules to make smoking less attractive.

In February, Dalli oversaw proposals that would tighten regulations on the use of flavouring in tobacco, which would have included non- such as snus, or Swedish snuff.

Snus is a moist powder tobacco originating from dry snuff. Though its sale is illegal across the EU, it is manufactured and used in Sweden, which has an exemption, and Norway, which is not an EU member.

Hildingsson said the alleged 60 million euro bribe to a Maltese businessman with links to Dalli would have been paid in two installments, with 10 million euros due before was enacted and the remaining 50 million to be paid when the new rules were in place.

add to favorites email to friend print save as pdf

Related Stories

EU health chief resigns in corruption scandal

Oct 16, 2012

(AP)—The European Union's health commissioner resigned Tuesday over corruption allegations involving tobacco laws but has denied any wrongdoing and has vowed to clear his name.

Study: Snuff users tend to obesity

Aug 25, 2006

A Swedish study finds that people who use snuff are more likely to be overweight and to have high blood pressure and high cholesterol.

Recommended for you

Amgen misses 1Q views as higher costs cut profit

Apr 22, 2014

Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed ...

Valeant, Ackman make $45.6B Allergan bid

Apr 22, 2014

Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

User comments